MED Alliance Group welcomes a new manufacturing partner — Tricol Biomedical, a global leader in hemostasis and infection control products. MED Alliance Group has partnered with Tricol to sell and distribute the HemCon Patch® Pro. Ideally suited for patients undergoing diagnostic and interventional catheterizations, the HemCon Patch® Pro quickly stops bleeding and provides a barrier to bacterial penetration of the dressing.
The HemCon brand was originally established in 2001 with its initial foundation in chitosan-based hemostatic solutions. Chitosan, derived from shrimp, is the unique clotting agent found in the HemCon Patch® Pro. This safe and cost-effective patch reduces hands-on compression time and quickly achieves hemostasis, even in anticoagulated patients. In addition, the patch provides an antibacterial barrier against 24 microorganisms, including Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococcal (VRE) and Clostridium difficile (C. difficile).
Tricol Biomedical, Inc.’s mission is to provide medical practitioners and consumers worldwide with the highest quality, most cost-effective bleeding control solutions and wound care management tools that improve outcomes throughout the continuum of care.
MED Alliance Group is dedicated to partnering with manufacturers offering high quality, cost-effective and innovative medical devices that improve patient care. We are delighted to add Tricol Biomedical to our portfolio of manufacturing partners.